| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6372252 | RB HLTH | Guaifenesin sustained release formulation and tablets |
Apr, 2020
(4 years ago) | |
| US7838032 | RB HLTH | Sustained release of guaifenesin |
Apr, 2020
(4 years ago) | |
| US6955821 | RB HLTH | Sustained release formulations of guaifenesin and additional drug ingredients |
Apr, 2020
(4 years ago) | |
Mucinex D is owned by Rb Hlth.
Mucinex D contains Guaifenesin; Pseudoephedrine Hydrochloride.
Mucinex D has a total of 3 drug patents out of which 3 drug patents have expired.
Expired drug patents of Mucinex D are:
- US6372252
- US7838032
- US6955821
Mucinex D was authorised for market use on 22 June, 2004.
Mucinex D is available in tablet, extended release;oral dosage forms.
Mucinex D can be used as expectorant and nasal decongestant.
The generics of Mucinex D are possible to be released after 28 April, 2020.
Drugs and Companies using GUAIFENESIN; PSEUDOEPHEDRINE HYDROCHLORIDE ingredient
Market Authorisation Date: 22 June, 2004
Treatment: Expectorant and nasal decongestant
Dosage: TABLET, EXTENDED RELEASE;ORAL
How can I launch a generic of MUCINEX D before it's drug patent expiration?
More Information on Dosage
MUCINEX D family patents
